CFR

Yield10 Bioscience Announces that the Plant Biosafety Office of the Canadian Food Inspection Agency has Cleared Genome-edited E3902 Camelina for Planting in Canada

Retrieved on: 
Tuesday, March 26, 2024
Canadian Food Inspection Agency, PNT, Yield10 Bioscience, Genome, Fishery, CFR, Livestock, Ministry, Genetically modified organism, Agriculture

E3902 Camelina remains subject to other applicable requirements of the Seeds Act and Regulations in Canada.

Key Points: 
  • E3902 Camelina remains subject to other applicable requirements of the Seeds Act and Regulations in Canada.
  • In addition to the recent regulatory determination in Canada, the Company has previously received favorable regulatory determinations for planting E3902 Camelina in the United States, Argentina, and Chile.
  • United States: In 2018, the U.S. Department of Agriculture determined that E3902 Camelina is not considered regulated under 7 CFR part 340.
  • 1523 of 2001, and its amendments regarding GMOs confirming that this line is not considered regulated in Chile and can be cultivated like conventional Camelina.

Thermo Fisher Scientific Innovations at Analytica 2024 Optimize Workflows and Enable Precise Analysis Across Life Sciences, Applied and Industrial Markets

Retrieved on: 
Tuesday, April 9, 2024
Technology, Biotechnology, Chemicals, Plastics, Health, Manufacturing, Other Education, Professional Services, Environment, Research, Education, Data Analytics, Hardware, Science, Green Technology, Environmental monitoring, Instrument, Quality control, QA/QC, Conference, Environmental chamber, Pharmacy, LIMS, Thermo Fisher Scientific, Laboratory, Investment, CFR, ULT, Data management, XRD

Analytica 2024 - Thermo Fisher Scientific, Inc. is debuting its recently launched innovative products, hosting educational presentations and showcasing live lab demos for customers working in laboratory technology, analysis, biotechnology, and environmental quality during the 2024 Analytica Conference.

Key Points: 
  • Analytica 2024 - Thermo Fisher Scientific, Inc. is debuting its recently launched innovative products, hosting educational presentations and showcasing live lab demos for customers working in laboratory technology, analysis, biotechnology, and environmental quality during the 2024 Analytica Conference.
  • “Advancements in data analytics and optimized laboratory workflows that enable fast, precise analysis are key to propelling the field of analytical science forward,” said Dan Shine, senior vice president and president, Analytical Instruments, Thermo Fisher.
  • Real-time monitoring with process analytical technology - The Thermo Scientific™ MarqMetrix™ All-In-One Process Raman Analyzer enables real-time, accurate spectral results for in-line, at-line, or on-line process monitoring.
  • For more information regarding Thermo Fisher products and services exhibited at Analytica 2024, please visit the website or booth 101 in hall B1.

Leading Cardiologists from NYU Langone Heart Present Latest Clinical Findings & Research at American College of Cardiology 73rd Annual Scientific Session

Retrieved on: 
Friday, April 5, 2024
Diagnosis, Internal medicine, Ozone, Cardiovascular disease, Eugene Braunwald, System, N95, Blood, Digital, Assistant, Memory, Risk, Diabetes, Inflammation, Patient, Biomarker, Research, Moyamoya disease, Cardiovascular Research, Splenic infarction, NYU, Ischemia, IMR, Particulates, Woman, Heart failure, American College, MPH, CFR, NYU Langone Health, EHR, American Red Cross, Bangladesh Technical Education Board, Air pollution, Data, Osteoarthritis, ACC, CCD, Work, Physician, Medical device

NEW YORK, April 5, 2024 /PRNewswire/ -- Experts from NYU Langone Heart are presenting their latest clinical findings and research discoveries during the American College of Cardiology (ACC) 2024 Annual Scientific Session & Expo, held April 6 to 8 in Atlanta.

Key Points: 
  • NEW YORK, April 5, 2024 /PRNewswire/ -- Experts from NYU Langone Heart are presenting their latest clinical findings and research discoveries during the American College of Cardiology (ACC) 2024 Annual Scientific Session & Expo, held April 6 to 8 in Atlanta.
  • "The ACC conference serves as a place for our faculty to explore, learn, and share all the latest advancements in the field.
  • They will also be available for media interviews to discuss innovative and noteworthy scientific developments emerging from the conference.
  • Her research is focused on understanding what makes heart attacks in women unique and the best methods of detection and treatment.

Gedeon Richter Selects Trial Interactive for Clinical Trial Management

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Cardiology, Health, Diabetes, Gedeon Richter, CNS, Rheumatology, Trial, Life, Neuropsychiatry, CFR, TMF, Osteoporosis, Blood, Pharmaceutical industry

The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.

Key Points: 
  • The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.
  • The Trial Interactive platform comprises clinical research-focused products that simplify tasks, oversight, compliance, and audits/inspections.
  • “The Trial Interactive eTMF will help us streamline our TMF operations and maintain inspection readiness.
  • Trial Interactive Division President Michael Smyth commented, “We’re proud to be part of Gedeon Richter’s plans for new studies and look forward to working more closely with their clinical operations teams through our TMF services.”

USDA-APHIS Determines that Yield10 Bioscience’s Omega-3 Camelina Varieties May Be Planted and Bred in the United States

Retrieved on: 
Thursday, March 21, 2024
USDA, DHA, Oil, Eicosapentaenoic acid, Rothamsted, Partnership, BRS, Sale, Weed control, Salmon, Yield10 Bioscience, EPA, CFR, RSR, Dicarboxylic acid, Genetic engineering, Dietary supplement

WOBURN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that USDA-APHIS’s Biotechnology Regulatory Services (“BRS”) has determined that Yield10’s Camelina sativa ("Camelina”) varieties developed using genetic engineering (modified Camelina) to produce omega-3 fatty acids are not subject to the regulations under 7 CFR part 340, and may be grown and bred in the United States. The global markets for omega-3 fatty acids include aquafeed used for salmon and trout farming, pet feed, baby formula, nutraceutical and pharmaceutical products. Most omega-3 fatty acids are produced from ocean-caught fish. Production constraints and supply volatility of traditional fish oil sources are creating gaps in supply and driving the growing demand for new sources of omega-3. Utilizing Camelina as a land-based production platform has the potential to provide a new, reliable supply for omega-3 fatty acids. Yield10’s submissions along with the USDA-APHIS BRS responses are posted on the USDA’s website.

Key Points: 
  • Utilizing Camelina as a land-based production platform has the potential to provide a new, reliable supply for omega-3 fatty acids.
  • An RSR filed in July 2023 covers Camelina engineered to produce eicosapentaenoic acid (“EPA”) where the engineered omega-3 Camelina produces oil containing approximately 16-20% EPA.
  • In 2020, Yield10 signed a collaboration agreement with Rothamsted to support Rothamsted’s Flagship Program to develop omega-3 oils in Camelina.
  • Yield10 is also engineering second generation omega-3 Camelina lines with herbicide tolerance traits to enable weed control in large-scale commercial planting of the crop.

Audubon Launches Unprecedented Vapor Recovery & Reuse System for EPA Compliance

Retrieved on: 
Tuesday, March 26, 2024
Packaging, Engineering, Chemicals, Plastics, Other Energy, Oil, Gas, Manufacturing, Energy, Ethanol, Gasoline, VUS, EPA, Volatile organic compound, NESHAP, CFR, Atmosphere, EPC, HAP

The unprecedented VUS advances vapor recovery functions by not only ensuring compliance with Environmental Protection Agency (EPA) regulations—it transforms toxic waste emissions into power or heat energy.

Key Points: 
  • The unprecedented VUS advances vapor recovery functions by not only ensuring compliance with Environmental Protection Agency (EPA) regulations—it transforms toxic waste emissions into power or heat energy.
  • The proprietary system captures waste vapor emissions according to new, stricter federal regulations and reuses them as an energy source.
  • Unlike traditional methods that merely remove waste vapor, the VUS converts it for power generation, electrical grid support, or renewable feedstock.
  • Audubon will work with its energy and industrial clients to support compliance with these standards for applications such as terminal loading, marine loading, fuel storage, and ethanol production, among others.

Cullen/Frost Bankers, Inc. Hosts First Quarter 2024 Earnings Conference Call

Retrieved on: 
Thursday, April 4, 2024
Senior, SAN, Webcast, Multimedia, Internet, Conference, Frost Bank, Central Time, CFR, CFO, Music

SAN ANTONIO, April 4, 2024 /PRNewswire/ -- Cullen/Frost Bankers, Inc. (NYSE: CFR) will host a conference call on Thursday, April 25, 2024 to discuss first quarter 2024 earnings.

Key Points: 
  • SAN ANTONIO, April 4, 2024 /PRNewswire/ -- Cullen/Frost Bankers, Inc. (NYSE: CFR) will host a conference call on Thursday, April 25, 2024 to discuss first quarter 2024 earnings.
  • Earnings Release: The earnings release for Cullen/Frost Bankers, Inc. will be available at approximately 8:00 a.m. Central Time (CT) on the internet at https://investor.frostbank.com/ .
  • Conference Call and Live Webcast: The conference call will begin at 1:00 p.m. CT (2:00 p.m. Eastern) and will be hosted by Phil Green, Chairman and CEO, Jerry Salinas, Group Executive Vice President and CFO and A.B.
  • Following the prepared remarks there will be a question and answer session for the analyst community.

Gedeon Richter Selects Trial Interactive for Clinical Trial Management

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Cardiology, Diabetes, Gedeon Richter, CNS, Rheumatology, Trial, Life, Neuropsychiatry, CFR, TMF, Osteoporosis, Blood, Pharmaceutical industry

BUDAPEST, Hungary and NEW YORK, March 25, 2024 /PRNewswire/ -- TransPerfect Life Sciences, a leading global provider of solutions for product development and launch for the biopharmaceutical industry, today announced that Gedeon Richter selected Trial Interactive's award-winning eTMF platform and TI Collaborate eClinical solution for its upcoming clinical trials.

Key Points: 
  • The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.
  • The Trial Interactive platform comprises clinical research-focused products that simplify tasks, oversight, compliance, and audits/inspections.
  • "The Trial Interactive eTMF will help us streamline our TMF operations and maintain inspection readiness.
  • Trial Interactive Division President Michael Smyth commented, "We're proud to be part of Gedeon Richter's plans for new studies and look forward to working more closely with their clinical operations teams through our TMF services."

Gedeon Richter Selects Trial Interactive for Clinical Trial Management

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Cardiology, Diabetes, Gedeon Richter, CNS, Rheumatology, Trial, Life, Neuropsychiatry, CFR, TMF, Osteoporosis, Blood, Pharmaceutical industry

BUDAPEST, Hungary and NEW YORK, March 25, 2024 /PRNewswire/ -- TransPerfect Life Sciences, a leading global provider of solutions for product development and launch for the biopharmaceutical industry, today announced that Gedeon Richter selected Trial Interactive's award-winning eTMF platform and TI Collaborate eClinical solution for its upcoming clinical trials.

Key Points: 
  • The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.
  • The Trial Interactive platform comprises clinical research-focused products that simplify tasks, oversight, compliance, and audits/inspections.
  • "The Trial Interactive eTMF will help us streamline our TMF operations and maintain inspection readiness.
  • Trial Interactive Division President Michael Smyth commented, "We're proud to be part of Gedeon Richter's plans for new studies and look forward to working more closely with their clinical operations teams through our TMF services."

FDA Roundup: March 22, 2024

Retrieved on: 
Friday, March 22, 2024
Health, Capecitabine, PFAS, FCN, Dietary supplement, OCE, Risk, COVID-19, Patient, Warning, Tablet, Public, RNA, DNA, Animal, News, Plasma protein binding, Emergency Use Authorization, Human services, Role, System, SARS-CoV-2, Physical examination, Plasmodium vivax, Plasmodium falciparum, Highlight, Malaria, Heated tobacco product, CFR, Vaccination, Safety, DPD, Cosmetics, Growth, Vaccine, Plasmodium ovale, Marketing, Food, FDA, Multimedia, Ponatinib

On Thursday, the FDA updated the Breakthrough Devices Program webpage to update the device designations data and the marketing authorizations list.

Key Points: 
  • On Thursday, the FDA updated the Breakthrough Devices Program webpage to update the device designations data and the marketing authorizations list.
  • From launch of the Breakthrough Devices Program through December 31, 2023, in total, the FDA granted 933 Breakthrough Devices designations and authorized 95 Breakthrough Devices for marketing.
  • On Thursday, the FDA approved safety labeling changes for fluorouracil injection products.
  • These changes also enable the FDA to more effectively respond to new information on the safety and use of food contact substances.